Nestle Health Science (NHSc) Exercises its Exclusive WorldWide Option to License CDX-6114 from Codexis
Shots:
- Codexis to receive $3M milestone and NHSc to get exclusive WW rights to develop and commercialize Codexis’s CDX-6114 for phenylketonuria (PKU)
- In 2017- Codexis & NHSc collaborated to develop CDX-6114 using Codexis’ CodeEvolver protein engineering platform paying $14M upfront and future milestones and granted an option to license for CDX-6114 to NHSc
- Codexis’s CDX-6114 is an enzyme involved in converting amino acid phenylalanine into tyrosine prevents further phenylalanine toxicity. CodeEvolver is a protein technology used for the development of therapies & proteins in multiple applications
Ref: Codexis | Image: Arab News
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
